Walgreens Health Services > Specialty Pharmacy > Limited-distribution drugs

Print

The following limited-distribution medications are available through Walgreens Specialty Pharmacy. (Manufacturers are listed in parentheses.)

Actemra® (Genentech USA, Inc.)
For the treatment of moderate to severe Rheumatoid Arthritis after at least one other tumor necrosis factor did not work.
More information at actemra.com

Amprya™ (Acorda Therapeutics, Inc.)
For the improvement of walking in patients with Multiple Sclerosis.
More information at acorda.com

Apokyn® (Tercica, Inc. a subsidiary of the Ipsen Group)
For the treatment of off-episode motor symptoms in people with advanced Parkinson's Disease.
More information at apokyn.com

Aralast NP™ (Baxter Healthcare)
For the treatment of patients with congenital alpha-1 antitrypsin deficiency who have been diagnosed with clinically evident emphysema.
More information at aralast.com

Arzerra™(GlaxoSmithKline)
For the treatment of patients with Chronic Lymphocytic Leukemia.
More information at gsk.com

Berinert® (CSL Behring)
For the treatment of acute abdominal or facial attacks of hereditary angioedema (HAE) in adult and adolescent patients.
More information at berinert.com

Dacogen® (Eisai, Inc.)
For the treatment of Myelodysplastic Syndromes.
More information at eisai.com

Epoprostenol (Teva Pharmaceuticals USA)
For the treatment of pulmonary arterial hypertension.
More information at tevausa.com

H.P. Acthar® Gel (Questcor Pharmaceuticals, Inc.)
For the diagnostic testing of adrenocortical function, and for the treatment of acute exacerbations of multiple sclerosis.
More information at acthar.com

Hycamtin® capsules (GlaxoSmithKline)
For the treatment of relapsed small cell lung cancer in patients with a prior complete or partial response and who are at least 45 days from the end of first-line chemotherapy.
More information at hycamtin.com

Increlex®(Tercica, Inc.)
For the treatment of growth failure in children with severe primary IGF-1 deficiency (primary IGFD) or with growth hormone (GH) deletion who have developed neutralizing antibodies to GH.
More information at increlex.com

Kuvan® (BioMarin Pharmaceuticals, Inc.)
For the treatment Phenylketonuria.
More information at kuvan.com

Letairis™(Gilead Sciences, Inc.)
For the treatment of pulmonary arterial hypertension.
More information at letairis.com

Lucentis® (Genentech USA, Inc.)
For the treatment of wet age-related macular degeneration.
More information at lucentis.com

Lumizyme™ (Genzyme Corporation)
For the treatment of late onset Pompe disease.
More information at www.lumizyme.com

Macugen® ((OSI)™ Eyetech, Inc. and Pfizer, Inc.)
For the treatment of wet age-related macular degeneration.
More information at macugen.com

Naglazyme® (BioMarin Pharmaceuticals, Inc.)
For the treatment of Maroteaux-Lamy syndrome.
More information at naglazyme.com

Nexavar® (Bayer HealthCare AG)
For the treatment of unresectable hepatocellular carcinoma and advanced renal cell carcinoma.
More information at nexavar.com

Oforta™(Sanofi-Aventis)
For the treatment of adult patients with B-cell chronic lymphocytic leukemia whose disease has not responded to previous treatment with an alkylating-agent containing regimen.
More information at sanofi-aventis.us

Promacta® (GlaxoSmithKline)
For the treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.
More information at promacta.com

Provenge™(Dendreon Corporation)
For the treatment of advanced prostate cancer.
More information at www.provenge.com

RiaSTAP™ (CSL Behring)
For the treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency.
More information at riastap.com

Revlimid® (Celgene Corporation)
For the treatment of multiple myeloma and transfusion-dependent anemia due to deletion 5q myelodysplastic syndromes.
More information at revlimid.com

Supprelin® LA (Endo Pharmaceuticals)
For the treatment of central precocious puberty.
More information at SupprelinLA.com

Synagis® (MedImmune, Inc.)
For the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus.
More information at synagis.com

Tracleer® (Actelion Pharmaceuticals USA, Inc.)
More information at tracleer.com

Tykerb® (GlaxoSmithKline)
For the treatment of advanced or metastatic HER2-positive breast cancer.
More information at tykerb.com

Tysabri® (Elan Pharmaceuticals, Inc.)
For the treatment of relapsing forms of multiple sclerosis and moderately to severely active Crohn’s disease.
More information at tysabri.com

Visudyne® (Novartis Pharmaceuticials Corporation)
For the treatment of wet age-related macular degeneration, pathologic myopia, and presumed ocular histoplasmosis.
More information at visudyne.com

Vivaglobin® (CSL Behring GmbH)
For the treatment of primary immune deficiency.
More information at vivaglobin.com

Votrient™ (GlaxoSmithKline)
For patients with advanced renal cell carcinoma.
More information at us.gsk.com

Vpriv™ (Shire Human Genetic Therapies, Inc.)
For the treatment of pediatric and adult patients with type 1 Gaucher disease.
More information at vpriv.com

Xiaflex™ (Auxilium Pharmaceuticals, Inc.)
For the treatment of adult patients with Dupuytren's contracture with a palpable cord.
More information at xiaflex.com

Xolair® (Genentech, Inc. and Novartis Pharmaceuticals Corporation)
For the treatment of moderate to severe persistent allergic asthma.
More information at xolair.com

Zorbtive® (EMD Serono, Inc.)
For the treatment of short bowel syndrome.
More information at zorbtive.com